Molecular Pharmacology Program
The Omar Abdel-Wahab Lab
Research
Omar Abdel-Wahab is the Chair of SKI Molecular Pharmacology Program, an Attending Physician on the Leukemia Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center, and the Director of Memorial Sloan Kettering’s Center for Hematologic Malignancies.
Featured News
Publications
People
Omar Abdel-Wahab, MD
Chair, Molecular Pharmacology Program, SKI; Attending Physician, Leukemia Service
- Physician-scientist Omar Abdel-Wahab studies the functional genomics of hematopoietic malignancies.
- MD, Duke University School of Medicine
- [email protected]
- Email Address
- View physician profile
- Physician profile
Members
Lab Alumni
Lab Affiliations
Achievements
- Josie Robertson Investigator (2012-2017)
- Seldin-Smith Award for Pioneering Research, American Society of Clinical Investigation
- Pershing Square Sohn Prize for Young Investigators in Cancer Research
- Leukemia & Lymphoma Society Clinical Scholar Award
- Joanne Levy Memorial Award for Outstanding Achievement, American Society of Hematology
Read more
- V Scholar Award, V Foundation
- Junior Faculty Scholar Award, American Society of Hematology (ASH)
- Damon Runyon Clinical Investigator Award
Get in Touch
-
Lab Head Email
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Omar Abdel-Wahab discloses the following relationships and financial interests:
-
AIchemy, Inc.
Ownership / Equity Interests; Provision of Services (uncompensated) -
Envisagenics
Ownership / Equity Interests; Provision of Services (uncompensated) -
Epizyme
Intellectual Property Rights
-
Harmonic Discovery Inc.
Ownership / Equity Interests -
Pfizer, Inc.
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].